Merck Serono initiates phase II study of Anti-PD-L1 antibody in mMCC
Biodel enters into $15 million equity commitment with Lincoln Park Capital
Allergan announces earnings and restructuring/layoffs, while still fighting Valeant
AbbVie and Shire - latest on the merger
Visit our sites for b2b sales and banking employees:
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Watson Pharmaceuticals | 1 | 13 | 1200 % |
| Aglos Pharmaceuticals | 1 | 9 | 800 % |
| Lexicon Pharmaceuticals | 1 | 8 | 700 % |
| Agios Pharmaceuticals | 1 | 8 | 700 % |
| Amag Pharmaceuticals | 1 | 7 | 600 % |
| Medidata Solutions | 1 | 7 | 600 % |
| La Jolla Pharmaceutical | 1 | 5 | 400 % |
| Royalty Pharma | 1 | 5 | 400 % |
| Idenix | 1 | 5 | 400 % |
| Edwards Lifesciences | 1 | 4 | 300 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Centron Diagnostics | 2 | 26 | 1200 % |
| CASMED | 1 | 9 | 800 % |
| Quark Pharmaceuticals | 4 | 29 | 625 % |
| Viking Systems | 2 | 14 | 600 % |
| Synthetic Biologics | 4 | 27 | 575 % |
| Aegerion | 9 | 59 | 556 % |
| Endologix | 2 | 13 | 550 % |
| Encision | 2 | 13 | 550 % |
| Alphatec Spine | 1 | 6 | 500 % |
| Cempra | 6 | 34 | 467 % |